NESS

BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing

Retrieved on: 
Wednesday, March 6, 2024

CAMBRIDGE, Mass. and NESS ZIONA, Israel, March 06, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (together with its subsidiaries and/or associates, “BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that it has entered into a definitive merger agreement with Adaptive Phage Therapeutics, Inc. (“APT”), a U.S.-based privately-held, clinical-stage biotechnology company pioneering the development of phage-based therapies to combat bacterial infections (the “Acquisition”). Immediately after the effective time of the Acquisition, and before giving effect to the concurrent private placement the former stockholders of BiomX will own approximately 55% and the former stockholders of APT will own approximately 45% of the consolidated entity of BiomX and APT. The Acquisition is expected to close within the next 30 days, subject to the satisfaction of the closing conditions described in the definitive merger agreement. Concurrently with entering into the definitive merger agreement, BiomX entered into a definitive purchase agreement for the sale of shares of newly created non-voting convertible preferred stock (“Series X Preferred Stock”) and warrants to purchase shares of BiomX common stock in a private placement to certain institutional accredited investors led by affiliates of Deerfield Management Company and the AMR Action Fund, and additional investors including the Cystic Fibrosis Foundation, OrbiMed and Nantahala Capital. The private placement is expected to result in gross proceeds to BiomX of $50 million before deducting placement agent and other offering expenses. The proceeds from the private placement are expected to provide funding through the results from a planned Phase 2b trial that will evaluate BiomX’s lead product candidate, BX004, for the treatment of chronic pulmonary infections caused by Pseudomonas aeruginosa (P. aeruginosa) in CF patients expected in the third quarter of 2025 and Phase 2 results from APT’s clinical-stage product candidate, now named BX211, for the treatment of Staphylococcus aureus (S. aureus) infections in DFO patients expected in the first quarter of 2025. The private placement is expected to close substantially concurrently with, and subject to the closing of, the Acquisition.

Key Points: 
  • Immediately after the effective time of the Acquisition, and before giving effect to the concurrent private placement the former stockholders of BiomX will own approximately 55% and the former stockholders of APT will own approximately 45% of the consolidated entity of BiomX and APT.
  • The Acquisition is expected to close within the next 30 days, subject to the satisfaction of the closing conditions described in the definitive merger agreement.
  • The private placement is expected to result in gross proceeds to BiomX of $50 million before deducting placement agent and other offering expenses.
  • The private placement is expected to close substantially concurrently with, and subject to the closing of, the Acquisition.

LexisNexis Names Lumus as One of the World's Top Innovators in "Innovation Momentum 2024: The Global Top 100" Report

Retrieved on: 
Monday, February 26, 2024

NESS ZIONA, Israel, Feb. 26, 2024 /PRNewswire/ -- Lumus, the pioneering developer of reflective or geometric waveguide technology for augmented reality (AR) eyewear, today announced that it has been named in the third annual "Innovation Momentum Global Top 100" report by LexisNexis®. The Top 100 recognizes companies advancing innovative solutions to today's challenges and laying the intellectual property foundations for further breakthroughs.

Key Points: 
  • The Top 100 recognizes companies advancing innovative solutions to today's challenges and laying the intellectual property foundations for further breakthroughs.
  • Lumus' robust portfolio includes more than 430 issued patents, with more than 540 patents pending, placing it among the world's top patent holders for augmented reality optics.
  • "Our patent portfolio reflects our strategy of maximizing our innovation potential through razor sharp focus and long-term persistence," said Lumus VP of Intellectual Property Mike Adel.
  • Innovation Momentum builds on the Patent Asset Index, a unique patent evaluation methodology featured in the analytics platform LexisNexis® PatentSight®.

Bioforum Signs Exclusive Deal to Acquire Assets from Abond CRO Inc., Expanding Reach of Global Biometric Services

Retrieved on: 
Tuesday, February 20, 2024

NESS ZIONA, Israel, Feb. 20, 2024 /PRNewswire/ -- Bioforum, the Data Masters, a leading contract research organization (CRO) focused on the delivery of biometric services and solutions to clinical trial sponsors worldwide, today announced that it has been exclusively selected by Abond CRO Inc., a full-service CRO that ceased operations in December 2023, to provide business continuity services to its biopharmaceutical and medical device customers around the globe. Under the terms of the agreement, Abond customers will have the opportunity to seamlessly transition to Bioforum and receive best-in-class data management and statistical analysis services to drive clinical trial efficiency. 

Key Points: 
  • Under the terms of the agreement, Abond customers will have the opportunity to seamlessly transition to Bioforum and receive best-in-class data management and statistical analysis services to drive clinical trial efficiency.
  • Several US-based biotechs and long-term Abond clients recently signed agreements with Bioforum.
  • Additionally, several former Abond executives have joined Bioforum, including subject-matter experts in statistical consulting and adaptive clinical trial design.
  • "Like Abond, Bioforum is passionate about accelerating clinical trials and providing a better experience for research stakeholders by optimizing critical processes and eliminating pain points that create burdensome inefficiencies," said Amir Malka, Bioforum's CEO and Co-Founder.

Ag-tech Start-Up WeedOUT Raises USD8.1 Million to Fight Weed Resistance

Retrieved on: 
Tuesday, February 20, 2024

NESS ZIONA, Israel, Feb. 20, 2024 /PRNewswire/ -- Ag-tech start-up WeedOUT, Ltd., announces it has secured USD8.1 million in A-round funding. Leading the round is Fulcrum Global Capital, a prominent US agri- focused VC with ties to a vast network of farmers across the US. The infusion of new capital will advance the company's mission to combat weed resistance through its breakthrough green solution.

Key Points: 
  • The infusion of new capital will advance the company's mission to combat weed resistance through its breakthrough green solution.
  • "Fulcrum Global is excited to support WeedOUT's cutting-edge biological platform and the unique approach it has pioneered to address the resistant weed problem.
  • The company's first target is the Palmer amaranth weed (Amaranthus palmeri), a major nuisance in the United States, Brazil, and Argentina.
  • The weed can grow up to several meters high and invade fields of corn, cotton, soybeans, and sugar beets.

NRGene Establishes Supree, a Food-Tech Company developing Self-Drying Fruits and Vegetables

Retrieved on: 
Tuesday, January 30, 2024

NESS ZIONA, Israel, Jan. 30, 2024 /PRNewswire/ -- NRGene Technologies Ltd. (TASE: NRGN) is pleased to introduce Supree (Supree-Zanim), its newly established FoodTech subsidiary, specializes in innovative fruit and vegetable varieties that naturally self-dry on the vine while maintaining nutritional value and flavor.

Key Points: 
  • The uniqueness of these varieties is in their skin's structure that is filled with microcracks which enables natural moisture evaporation.
  • Supree's semi-dried tomatoes are perfect for various culinary applications from snacks, salads and cooked dishes, baked goods, and even desserts.
  • The thawed product retains its quality, texture, and nutritional value and is available throughout the year, regardless of growing season.
  • Tomato powder derived from these tomatoes enriches processed food products across various industries, including meat products, meat substitutes, healthy beverages, and snacks.

NRGene Establishes Supree, a Food-Tech Company developing Self-Drying Fruits and Vegetables

Retrieved on: 
Tuesday, January 30, 2024

NESS ZIONA, Israel, Jan. 30, 2024 /PRNewswire/ -- NRGene Technologies Ltd. (TASE: NRGN) is pleased to introduce Supree (Supree-Zanim), its newly established FoodTech subsidiary, specializes in innovative fruit and vegetable varieties that naturally self-dry on the vine while maintaining nutritional value and flavor.

Key Points: 
  • The uniqueness of these varieties is in their skin's structure that is filled with microcracks which enables natural moisture evaporation.
  • Supree's semi-dried tomatoes are perfect for various culinary applications from snacks, salads and cooked dishes, baked goods, and even desserts.
  • The thawed product retains its quality, texture, and nutritional value and is available throughout the year, regardless of growing season.
  • Tomato powder derived from these tomatoes enriches processed food products across various industries, including meat products, meat substitutes, healthy beverages, and snacks.

BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis

Retrieved on: 
Thursday, January 4, 2024

and NESS ZIONA, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that its phage cocktail, BX004, has been granted Orphan Drug Designation (“ODD”) by the United States Food and Drug Administration (“FDA”), for the treatment of chronic pulmonary infection caused by Pseudomonas aeruginosa (or P. aeruginosa) in patients with cystic fibrosis (“CF”).

Key Points: 
  • and NESS ZIONA, Israel, Jan. 04, 2024 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) (“BiomX”), a clinical-stage company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that its phage cocktail, BX004, has been granted Orphan Drug Designation (“ODD”) by the United States Food and Drug Administration (“FDA”), for the treatment of chronic pulmonary infection caused by Pseudomonas aeruginosa (or P. aeruginosa) in patients with cystic fibrosis (“CF”).
  • As a reminder, in August 2023, the FDA granted BX004 Fast Track designation for the treatment of chronic pulmonary infections caused by P. aeruginosa bacterial strains in patients with CF.
  • “We are pleased to announce that the FDA has granted BX004 Orphan Drug Designation, which underscores the pressing need to develop new and innovative treatment options for this vulnerable patient population,” said Jonathan Solomon, Chief Executive Officer of BiomX.
  • “Persistent and deadly pulmonary infections from P. aeruginosaremain a major source of morbidity and mortality for CF patients, andBX004 has been designed to address this significant unmet need.

Bsense Announces the Clinical Candidate Nomination of BSEN760, a Novel Dual Kv7.2/3 and TRPV1 Modulator, to Unlock a New Approach to Dampening Sensory Hyperexcitability for Chronic Pain Treatment

Retrieved on: 
Tuesday, December 5, 2023

BSEN760 is a novel potent and selective, orally active, investigational small molecule drug that simultaneously activates Kv7.2/3 and inhibits TRPV1.

Key Points: 
  • BSEN760 is a novel potent and selective, orally active, investigational small molecule drug that simultaneously activates Kv7.2/3 and inhibits TRPV1.
  • The dual mechanism of action (MOA) of BSEN760 underlies the compound’s exquisite potency and synergistic activity in dampening sensory neuron hyperexcitability.
  • As such, BSEN760 may enter the market with comparable, potentially better, efficacy vs. SOC, and a much improved safety profile.
  • These, and other data, support the Company’s efforts toward full preclinical development of BSEN760 and IND submission by Q1 2025.

BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023

Retrieved on: 
Thursday, November 30, 2023

(University of California, San Diego), who will discuss phage therapy, the current treatment landscape, and the unmet medical need in cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (P. aeruginosa) respiratory infections.

Key Points: 
  • (University of California, San Diego), who will discuss phage therapy, the current treatment landscape, and the unmet medical need in cystic fibrosis (CF) patients with chronic Pseudomonas aeruginosa (P. aeruginosa) respiratory infections.
  • Jonathan Solomon, Chief Executive Officer of BiomX, will review topline results from Part 2 of the Phase 1b/2a trial evaluating the Company’s novel phage cocktail, BX004, as a potential treatment for chronic pulmonary infections caused by P. aeruginosa in CF patients.
  • BiomX is developing BX004, utilizing its proprietary BOLT platform, to address a significant unmet need facing thousands of CF patients who require new treatments to combat persistent and deadly lung infections.
  • P. aeruginosa is a main contributor to morbidity and mortality in patients with CF.

Sol-Gel Technologies Screens First Patient for SGT-610 Phase 3 Study

Retrieved on: 
Thursday, November 30, 2023

Patidegib was acquired by Sol-Gel from PellePharm and is currently the only therapy in development to prevent the development of new BCC lesions in Gorlin syndrome patients.

Key Points: 
  • Patidegib was acquired by Sol-Gel from PellePharm and is currently the only therapy in development to prevent the development of new BCC lesions in Gorlin syndrome patients.
  • "We are pleased to initiate patient screening in this Phase 3 trial that has been long awaited by the Gorlin syndrome patient community,” said Alon Seri-Levy, Ph.D., Chief Executive Officer of Sol-Gel.
  • Sol-Gel will conduct the Phase 3 study to investigate SGT-610 in approximately 140 subjects at approximately 40 experienced clinical centers in North America, United Kingdom and Europe.
  • The event will highlight the patient’s experience through the eyes of a Gorlin syndrome patient as well as discuss the therapeutic potential of SGT-610 to prevent new BCCs in Gorlin syndrome patients and Sol-Gel’s Phase 3 trial.